MET and glioblastoma: MET is a critical player and therapeutic target in tumorigenesis [176,177]; nevertheless, a combination of onartuzumab, an antibody blocking c-MET (Figure 3), with bevacizmab resulted in no additional benefit over anti-VEGF-A monotherapy in recurrent GBM [178].